L&C BIO

At a glance

L&C BIO filed 86 disclosures in the last 12 months, including 23 insider, 12 5% holder, 4 earnings, 2 issuance and 1 buyback. The most recent key filing was on Oct 30: President's holding rose by 25,569 sh (other change, rights offering, bonus issue).

Revenue for 2025 was ₩85.5B, up 18.7% on 2024. Operating margin was 5.2% against 5.4% a year earlier. Debt was 119% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩69.1B and operating profit of ₩14.6B.

The 2025 annual report lists 155 employees with an average tenure of 3.5 years and average pay of ₩49.8M, #1456 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩130.2M each on average. It paid ₩50 per common share in cash dividends, against ₩50 a year earlier (+0%). 이환철 and related parties held 26.93% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 20.59% on Oct 30.

From the 2025 annual report

Staff: 155 (90 men, 65 women), of whom 10 on fixed-term contracts. Total pay for the year: ₩7.2B. Directors and auditors: 5, paid ₩651.2M in total.

Dividends (common shares)

Largest shareholder

이환철 holds 25.69%; with 10 related parties the group holds 26.93% of common shares at year end (from 31.66% at the start of the year).

Auditor: 한울회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports